摘要
目的探讨多发性骨髓瘤(MM)患者β2-微球蛋白(β2-MG)测定的临床意义。方法采用微粒子酶免疫法测定40例MM患者和30例正常对照者血、尿β2-MG,同时还测定血红蛋白、肌酐、血沉、钙。结果正常组与MM组,I、Ⅱ、Ⅲ期患者治疗前与治疗后血、尿β2-MG差异有统计学意义(P<0.01)。Ⅲ期与Ⅱ期,Ⅱ期与I期治疗前的血、尿β2-MG差异均有统计学意义(P<0.01)。结论β2-MG水平与MM的发生发展有密切关系,并且可以作为MM临床分期以及预后的重要指标。
Objective To analyze the clinical significance of determination of β2- MG in patients with multiple myeloma. Methods β2- MG in serum and urine of 40 multiple myeloma patients was determined by micro particle enzyme immunoassay. Meanwhile erythrocyte sedimentation rate, hemoglobin, creatinine, calcium were also determined. Results The levels of β2-MG in serum and urine of patients with multiple myeloma patients before treatment were signifieantly higher than those in control （ P 〈 0. 01 ）. The levels of β2- MG in serum and urine of patients in groupⅠ ,Ⅱ and Ⅲ after treatment were significantly lower than those before treatment （ P 〈 0.01）. Conclusion The level of β2- MG is closely associated with the occurrence and development of multiple myeloma and it is valuable for the classification and the judgment of therapeutic effect.
出处
《中国热带医学》
CAS
2007年第2期248-249,共2页
China Tropical Medicine
